 |
HOW MUCH DOES SLACTIVE COST? WHAT IS THE WAY FORWARD?THE DENTISTS USING SLACTIVECONTACT US FOR SLACTIVE |
Visit DentistAbroad's main website here
Source: www.straumann.com
SLActive
Groundbreaking clinical results support strong SLActive performance
SLActive, the next generation in implant technology, was officially launched at the 14th Annual Scientific Congress of the European Association for Osseointegration (EAO) in Munich in September 2005.
SLActive is supported by more scientific studies than any other dental implant technology at the time of market launch.
Surface innovation
From surface topography to surface chemistry
We look back on a long tradition of pioneering implant surfaces, having developed the ground-breaking SLA® surface in 1994.
This surface reduced the average healing time from 12 weeks (TPS surface) to only 6-8 weeks. Shortly after its introduction, the macro- and microstructured, osseoconductive SLA surface became the gold standard in implant technology.
The SLActive surface takes the proven concept of SLA one step further to set the new surface benchmark. Due to its molecular optimization and the substantial reduction of the average healing time from 6-8 weeks to 3-4 weeks, SLActive offers new treatment possibilities for the challenges in your daily practice.
Product packaging
To maintain the active and hydrophilic state of the surface after the production process, SLActive is stored in an isotonic sodium chloride solution contained in the SLActive-specific implant vial. Biology-inspired innovation
Activating the healing potential
SLActive is based on the scientifically proven SLA® surface topography, but exhibits a fundamentally improved surface chemistry. Due to its ideal conditioning, the chemically active and hydrophilic SLActive surface significantly promotes the initial healing reaction.
Animal studies demonstrate that our new surface allows for accelerated bone remodelling during the entire osseointegration process. In short, SLActive activates the healing response.
Understanding surface chemistry
Surface chemistry refers to the molecular and atomic structure on the implant surface.
SLActive is a hydroxilated (chemically active) surface. Such a surface chemistry provides ideal conditions for direct protein adsorption and thus immediate initiation of implant integration in the human body.
Understanding hydrophilicity
Hydrophilicity (wettability)
Hydrophilicity describes the property of being water-attracting. In the context of SLActive, it describes the ability of the surface to directly absorb blood into its micropores right after implant placement.
Hydrophilicity (also referred to as ‘wettability’) is quantified by the contact angle of a water drop to a surface. All surfaces currently available in the market are hydrophobic (i.e. water-repellent).
Cutting-edge production technology
Cutting-edge biology-inspired products require state-of-the art production and packaging. SLActive is produced by means of a production process in which the implant surface is processed under nitrogen atmosphere.
This modification of the production process facilitates the enhancement and preservation of the hydrophilic properties of SLActive. Production process
The reason for the chemical activity of SLActive is a modified production process that is illustrated in the graphic below.
Step 1 SLA® and SLActive are both sand-blasted and acid-etched, which results in an identical macro- and microstructure*.
Step 2 Through rinsing with water, both surfaces form a hydroxylated, chemically active (charged) surface layer with hydrophilic properties.
Step 3a SLA – By air-drying SLA, the hydroxylated, chemically active surface layer cannot be maintained. Air contact causes a passive layer of hydrocarbons to form.
Step 3b SLActive – With the novel SLActive conditioning carried out in nitrogen atmosphere, the chemically active and hydrophilic surface state is maintained. Subsequent storage of the surface in a sodium chloride solution preserves these characteristics.
* The macrostructure offers the ideal topography for attachment of bone cells with a diameter of 20–40 µm. The microstructure is optimal for the attachment of the “arms” (filopodia) of the bone cells to the surface and measures 2–4 µm. Eliminate the dip
Eliminate the stability dip!
Clinical experience shows that most implant failures occur in the critical early treatment period of the first eight weeks after implant placement. This is due to the delayed healing process of the bone and thus limits the application of novel implant treatment techniques, i.e early loading. Looking at the rapid increase in implants placed and the application of aggressive treatment techniques, there is a growing need to reduce the risk during this early treatment phase.
SLActive has been developed to optimize early implant stability, to reduce the risk during the critical early treatment. Animal test results show that SLActive provides 60% more bone* (compared to SLA®); these tests in conjunction with clinical results also reveal a significantly improved implant stability after two weeks** (compared to SLA). For the challenges in daily practice, SLActive offers higher treatment predictability and security for clinicians and patients.
* D. Buser, N. Broggini, M. Wieland, R. Schenk, A. Denzer, D. Cochran, B. Hoffmann, A. Lussi, S. Steinemann. Enhanced bone apposition to a chemically advanced SLA titanium surface. Published 07/2004, JDR 83 (7): 529 – 533, 2004.
** Raghavendra S, Wood MC, Taylor TD. Early wound healing around endosseous implants: a review of the literature. Int J Oral Maxillofac Implants. 2005 May-Jun;20(3):425-31.
Stability pattern
SLActive reduces the risk during the critical early treatment by accelerating and optimizing implant integration. The bone formation process is initiated at an earlier stage, resulting in radically improved implant stability in the ‘critical dip’ period.
This stability improvement is illustrated in the graph by the blue line and the corresponding orange line indicating total stability.
Total stability (orange line)
The sum of primary and secondary stability is referred to as total stability. The terms primary and secondary stability are explained under osseointegration. Understanding osseointegration
In the osseointegration process, two factors play an important role: Primary stability (mechanical stability) and secondary stability (biologic stability after bone remodelling) of the implant in the bone. With conventional surfaces, implants are exposed to a higher risk of failure due to an overall stability dip between weeks two to four.
Primary stability
As soon as an implant is placed into the jawbone, certain areas of the implant surface are in direct contact with the bone. This contact is called primary or mechanical stability and depends on implant shape, bone quality and implant bed preparation. The primary stability gradually decreases in the bone remodelling process.
Secondary stability
In the healing process, the bone is remodelled and forms new contact areas with the implant surface. This new bone contact is called secondary or biological stability. When the healing process is complete, the initial mechanical stability is fully replaced by biological stability.
Clinical impact
Reduced healing time
Developed in 1998, SLA® set the gold standard by halving the average healing time from 12 weeks to 6-8 weeks. SLActive cuts the healing time once more in half by reliably offering sufficient secondary stability for early loading already at 3-4 weeks after implant placement.
Higher treatment predictability and reduced risks
Compared to SLA, SLActive provides 60% more bone-to-implant contact two weeks after insertion, as shown in animal tests. This substantially higher BIC-value results in improved treatment predictability for all protocols and helps to minimize the potential for early implant failures. New treatment options
Although implants with SLActive surface are suitable for all indications, the high treatment-security they provide render them especially beneficial to advanced and complex treatment protocols in challenging indications.
Frequently Asked Questions
Is SLActive supported by scientific data gained from clinical studies?
Has the improvement of the Gold Standard SLA® with SLActive been proven in clinical studies?
Is SLActive only active for 15 minutes after removal from the vial?
Can SLA be made hydrophilic and active by immersion in Sodium Chloride?
Why is the healing time important if immediate loading is also possible with standard surfaces?
Is early loading possible for all implant types and indications after 3-4 weeks?
Is SLActive supported by scientific data gained from clinical studies?
Yes. SLActive is supported by more scientific studies than any other dental implant technology at the time of market launch. Ten preclinical and three clinical studies have been completed or are ongoing. All of them show significant and positive results.
Has the improvement of the Gold Standard SLA with SLActive been proven in clinical studies?
Yes. The SLActive Impact Study 3 “Osstell” (by Cochran & Bischof/Nedir) shows a highly significant stability difference between SLActive and SLA. Clinical studies in humans showed that the stability pattern is improved with SLActive. The results indicate that implants with SLActive reached full stability two weeks earlier than implants with SLA.
Is SLActive only active for 15 minutes after removal from the vial?
We suggest placing the implants with SLActive within 15 min. after being removed from the vial. Tests have shown that even after drying the surface remains hydrophilic and chemically active for a certain period of time.
Can SLA be made hydrophilic and active by immersion in Sodium Chloride?
No. Even if you let an implant with SLA rest in a saline solution for several hours, the implant will keep its passive surface layer. SLActive is the result of a highly complex and innovative production process under Nitrogen atmosphere.
Why is the healing time important if immediate loading is also possible with standard surfaces?
Immediate loading protocols exist for SLA, SLActive and other surfaces. The different surfaces show varying success rates. The majority of implant failures occur in the early treatment phase. By reducing the healing time with SLActive, the critical stability period can be reduced to a minimum.
Is early loading possible for all implant types and indications after 3-4 weeks?
Pre-clinical and clinical studies prove that SLActive accelerates bone formation significantly in comparison to SLA. Substantial evidence on this claim is provided by two clinical studies: the Osstell study and the SLActive Impact Study “Multicenter”. The latter, assessing almost 400 implants in patients, shows that immediate and early loading (defined as 4 weeks after implant placement) are very promising and predictable protocols for SLActive.
Source: www.straumann.com
SLActive